Skip to main content
. Author manuscript; available in PMC: 2017 Nov 10.
Published in final edited form as: Adv Mater. 2017 Jul 6;29(33):10.1002/adma.201700141. doi: 10.1002/adma.201700141

Scheme 1.

Scheme 1

Schematic illustration of the polyMTO-based NP platform for targeted and deeply penetrating cancer therapy. After intravenous injection, the iRGD-mediated targeting strategy facilitates the tumor tissue penetration and tumor cell uptake of the NPs (a, b). Subsequently, the high level of ROS in cancer cells can break thioketal bond in the polyMTO to induce chain-breakage patterned release of intact MTO release (c) for disrupting DNA synthesis and efficient cancer therapy (d).